Imaging Modalities for Focal Nodular Hyperplasia and Hepatocellular Adenoma

Jacomina W. van den Esschert a Thomas M. van Gulik a Saffire S.K.S. Phoa b

Departments of a Surgery and b Radiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Key Words
Liver cell adenoma · Focal nodular hyperplasia · Magnetic resonance imaging · Ultrasound · Spiral computed tomography · Radionuclide imaging

Abstract
Background/Aims: There are several imaging modalities available for the detection of focal liver lesions. Differentiation between focal nodular hyperplasia (FNH) and hepatocellular adenoma (HCA) is important because of the consequences for management. However, differentiation based on imaging alone still shows limitations. Methods: We reviewed the literature for typical features of FNH and HCA on radiologic and nuclear imaging with emphasis on differentiation of both lesions. Results: Seven articles describe the performance of an imaging modality for the differentiation between FNH and HCA. Limitations of these studies are the small sample size and/or the lack of comparison with the ‘gold standard’, i.e. histological diagnosis. No studies are available that compare the accuracy of several imaging modalities in the differentiation of FNH and HCA. Conventional ultrasound (US) is not useful in the differentiation because of the non-specific features. On contrast-enhanced US, the arterial filling direction of FNH is centrifugal and centripetal in case of HCA. The parenchymal enhancement of FNH is sustained in the portal venous and delayed phases, but shows rapid washout in case of HCA. Multiphase CT scan can differentiate FNH from HCA when there is a central scar. FNH may have a slightly higher relative enhancement in the arterial phase. On MRI with hepatocyte-specific contrast agents, HCA does not show contrast uptake in the hepatobiliary phase in contrast to FNH. Conclusion: We conclude that there is limited evidence of the diagnostic performance of currently used imaging modalities for the differentiation of FNH and HCA. We therefore propose a prospective study (DiFA trial) to determine the accuracy of several radiologic and nuclear imaging studies in differentiating FNH and HCA.

Introduction

Due to the increased use of abdominal imaging, benign liver tumors are detected as an incidental finding more frequently. Focal nodular hyperplasia (FNH) and hepatocellular adenoma (HCA) are both benign lesions which predominantly occur in young and middle-aged women. Differentiation of FNH from HCA is important because of the consequences for management of both these lesions. HCA carries a risk of spontaneous bleeding and malignant transformation as pointed out elsewhere in this issue [1, 2].
Differentiation may be difficult based on imaging studies alone, because of the radiological similarities of both tumors. Biopsy and histological assessment of the tumor for a definitive diagnosis of FNH or HCA is mandatory in such cases [3]. In recent years many new imaging modalities have been introduced, e.g. MRI with hepatobiliary contrast agents and contrast-enhanced ultrasound (US). The question arises which imaging modality performs best in differentiating FNH from HCA, and whether we can rely on imaging for diagnosis rather than to obtain histopathological confirmation.

We reviewed the literature for studies that described the typical features of FNH and HCA on several imaging modalities, and for studies that focused on the ability of imaging modalities in differentiating FNH from HCA.

**Methods**

The literature was reviewed for typical features of FNH and HCA on radiologic and nuclear imaging (US, multiphase CT, MRI and nuclear imaging) with emphasis on differentiation of both lesions. A literature search was performed using the Medline database. The applied search terms were a combination of the MeSH terms ‘focal nodular hyperplasia’, ‘liver cell adenoma’, ‘magnetic resonance imaging’, ‘ultrasound’, ‘spiral computed tomography’ and ‘radionuclide imaging’ with addition of the word ‘differentiation’. The search was limited to English language. Additional articles were reviewed from the bibliography of articles cited.

**Results**

Of the 55 hits, 7 studies specifically assessed the use of an imaging modality in the differentiation of FNH and HCA. These studies are discussed below.

**Ultrasound**

Both FNH and HCA show non-specific features on gray-scale US. FNH is usually slightly hypo- or isoechoic and very rarely hyperechoic. Sometimes the lesion is only detected by visualization of a pseudocapsule which is due to compression of the surrounding liver tissue or vessels. A central scar and septae are typical findings of FNH, but more than half of the FNH are devoid of a central scar [4–8]. HCA is also hypoechoic in the majority of cases. However, HCA may appear hyperechoic because of abundant fat, fibrosis, or bleeding inside HCA. Calcifications may be present and show up as hyperechoic foci with acoustic shadowing [9, 10].

Color Doppler US is able to show peri- and intratumoral vessels [10–12]. Bartolozzi et al. [13] performed a Doppler US study in which they compared power Doppler and color Doppler sonography in 29 patients with 22 histologically proven FNHs and 9 HCAs. FNH was characterized by the presence of multiple well-defined vessels with a pulsatile Doppler spectrum radiating from the center to the periphery of the lesion. This finding was present in 91% of the lesions on power Doppler and in 68% on color Doppler sonography. In contrast, HCA showed vessels running along the periphery of the lesion associated with multiple vascular pedicles in the central portion with a venous Doppler spectrum, in 89 and 67% on power Doppler and color Doppler sonography, respectively. Power Doppler imaging appeared to be superior to color US in the depiction of those intratumoral flow characteristics.

To improve the characterization of liver lesions on US, contrast agents consisting of microbubbles have been developed. Nowadays, second-generation contrast agents (e.g. Sonovue; Bracco Imaging, Milan, Italy) and continuous (real-time) US scanning are often used. Burns and Wilson [14] assessed the concordance of enhancement patterns of focal liver lesions on contrast-enhanced US with patterns on contrast-enhanced CT and MRI. They concluded that US showed a high concordance with arterial phase CT or MRI. This concordance was much less for the portal phase, probably due to lack of diffusion of the microbubbles into the interstitium.

After contrast administration, FNH typically shows centrifugal filling preceded by a spoke-wheel pattern enhancement in the early arterial phase. This spoke-wheel pattern is less present in lesions <3 cm. During the portal venous and delayed phases, FNH appears hyper- or isoechoic in comparison with surrounding liver parenchyma. The presence of a non-enhancing central scar was found to be a distinctive feature of FNH [15–23]. HCA shows subcapsular feeding arteries with mixed or centrifetal filling. The clear enhancement in the arterial phase becomes less intense in the portal venous and delayed phases [24].

Dietrich et al. [25] performed a study in 32 patients to differentiate FNH from HCA with contrast-enhanced US. All lesions showed pronounced enhancement in the arterial phase. In the portal phase, 96% of patients with FNH showed sustained enhancement. In contrast, all patients with HCA showed rapid washout of the contrast leading to no enhancement during the portal venous phase. Kim et al. [26] performed a retrospective study to determine the differential features of FNH and HCA on
contrast-enhanced US. Their conclusion was that the features in the early arterial phase contributed most to the differentiation of FNH and HCA by showing the arterial phase filling direction and arterial morphology. FNH showed centrifugal filling (74–91%) and stellate vascularity (60–67%), whereas HCA was less reliably predicted by centripetal or mixed filling (86%) without stellate vascularity (11–16%). They concluded that sustained portal enhancement was more common in FNH (86–91%) than in HCA (47–63%).

In short, conventional US is not useful in differentiating FNH from HCA because of the non-specific features, except for a central scar. On Doppler US and contrast-enhanced US, FNH typically shows centrifugal, arterial vascularity and HCA typically shows centripetal vascularity with a flat continuous Doppler spectrum. The additional value of real-time US with microbubble contrast lies in the enhancement pattern of the liver parenchyma. Both lesions show pronounced enhancement in the arterial phase. In case of FNH, parenchymal enhancement sustains in the portal venous and delayed phases, but in case of HCA washes out rapidly.

**Multiphase CT Scan**

Many studies assessed the use of multiphase CT scan for the detection of focal liver lesions, including FNH and HCA. On plain CT scan, FNH is usually homogeneous and iso- or slightly hypointense compared to normal liver tissue. In case of steatosis of the liver parenchyma, FNH may appear hyperintense due to the low attenuating fatty liver [27, 28]. Calcifications are rarely seen [27, 29, 30]. HCA may show a variety of density patterns on plain CT scan due to fat, necrosis or hemorrhage. Calcifications are more common than in FNH and are present in 5–15% of the lesions [31].

After contrast administration, rapid homogeneous enhancement of well-delineated, lobular-shaped FNH is seen in the arterial phase with a hypodense central scar in some cases. An enlarged feeding artery is often visible. In the portal venous and delayed phase, the FNH becomes isodense and may be difficult to detect. The central scar and septations typically show late enhancement due to diffusion of the contrast material into the stroma of the lesion [4, 27, 28, 30, 32–37]. A central scar is seen on CT in approximately 50% of the lesions. Large FNHs (>3 cm) are significantly more likely to reveal central scarring, vascular displacement and abnormal vessels around the lesions than smaller lesions [27, 38]. A pseudocapsule is seen in 8% of the FNHs [27]. A well-circumscribed HCA also becomes hyperdense in the early arterial phase and slightly hyper- to isodense in the portal phase. Peripheral enhancement may be seen reflecting the presence of the large subcapsular feeding vessels [10]. On delayed phase imaging, a washout phenomenon may occur when contrast washout is rapid, rendering the lesion hypodense in comparison to the surrounding liver tissue. A pseudocapsule is present in 25–30% of the HCAs [10, 31].

Ruppert et al. [36] performed a study in 45 histologically proven FNHs and 27 HCAs to evaluate the use of triphasic CT imaging for differentiating FNH and HCA. They found a central scar in 65% of all FNHs (29% in FNH <3 cm and 82% in FNH >3 cm) and none in case of a HCA. Subcapsular arteries were detected in none of the FNHs and in 39% of the HCAs. In addition, they quantified dynamic enhancement patterns. FNH enhanced more homogeneously and arterial enhancement was stronger than in HCA. HCA showed more washout in the portal phase; 22% of the HCAs were hypodense, whereas FNH remained iso- or hyperdense. They concluded that FNH can reliably be diagnosed if relative enhancement is >1.6 in the arterial phase.

In conclusion, multiphase CT scan can differentiate FNH from HCA based on the presence of a central scar, the slightly higher relative enhancement in the arterial phase and the presence of central feeding arteries. However, these findings are not always present or visible on CT (fig. 1, 2). HCA shows heterogeneous densities on plain CT due to fat, necrosis, hemorrhage or calcifications and a washout phenomenon may occur.

**MRI Scan**

Owing to high soft-tissue contrast of MRI, FNH and HCA can be depicted on non-enhanced MRI. Almost all FNH lesions are slightly hyper- or isointense or not visible on T₂ images of unenhanced MRI. A central scar, typically hyperintense, may be seen in approximately 30% of the lesions, mostly in the lesions >3 cm. On the T₁ images, most lesions are iso- or slightly hypointense while the central scar appears hypointense [39–48]. HCA is also mainly slightly hyper- to isointense on T₂ images. On T₁ images, all possible signal intensities are mentioned in the literature. For example, Grazioli et al. [41] showed that HCA was iso- or slightly hypointense in 74% and slightly hyperintense in 20% of the lesions. Chung et al. [49] also showed that the minority of the lesions were hyperintense (35%), while according to Paulson et al. [50] and Arrive et al. [51], HCA appeared hyperintense in 51 and 59% of the cases, respectively. HCA may show a more heterogeneous signal intensity than FNH due to hemorrhage, fat or ne-
crosis. MRI is superior to CT in detecting small amounts of fat in the liver or in a focal liver lesion, using in- and out-of-phase imaging sequences. Old bleeding in the lesion may cause a scar-like appearance (fig. 3).

There are several liver-specific contrast agents available for MRI. Superparamagnetic iron oxide (SPIO) and USPIO (ultrasmall SPIO) particles are taken up by the reticuloendothelial system. Uptake by Kupffer cells will lead to a loss of signal of the liver on T2-weighted MR images [47, 53, 54]. The iron oxide particles are used to better detect lesions in the liver that do not contain Kupffer cells, e.g. metastasis. In FNH the amount of functional Kupffer cells is higher than in HCA. Therefore, FNH demonstrates more signal loss on MRI after ferumoxide.
compared to HCA. However, the diagnosis of FNH cannot reliably be made on the basis of ferumoxide as contrast agent [39, 55, 56].

Mangafodipir trisodium (Teslascan; Amersham Health, Oslo, Norway) is a MR contrast agent that is selectively taken up by hepatocytes, leading to increased signal intensity on T₁-weighted images in normal liver parenchyma. It is excreted via the biliary system. With this contrast agent, hepatocyte-containing liver tumors can be differentiated from tumors of non-hepatocyte origin, e.g. metastases [55, 57].

Gadobenate dimeglumine (Gd-BOPTA, Multihance; Bracco Imaging) and gadoxetic acid (Gd-EOB-DTPA, Primovist; Schering) are both contrast media with combined perfusion and hepatocyte-selective properties. Firstly, these contrast media are visible during the vascular phase due to the non-specific gadolinium chelates. Secondly, they are partly taken up by hepatocytes and excreted into the bile ducts [58]. The latter property is of importance in the differentiation of FNH and HCA, because HCA does not contain bile ducts in contrast to FNH (fig. 4, 5).

Grazioli et al. [41] performed a prospective, multicenter study to differentiate FNH from HCA with MRI and Gd-BOPTA in 73 patients with FNH, 27 with HCA, and 8 with adenomatosis. On T₁-weighted images, 95% of the FNHs appeared homogeneously hyperintense in the arterial phase. In the portal venous and equilibrium phases, the FNHs remained slightly hyperintense (47 and 33%, respectively) or became isointense compared to the surrounding liver parenchyma. The central scar was mainly seen as a hypointense feature in the arterial phase and became hyperintense in the equilibrium phase. The enhancement pattern of HCA was similar to that of FNH after contrast administration, i.e. hyperintense in the arterial phase (96%) and hyper- to isointense in the portal venous and equilibrium phases. In the hepatobiliary phase, when contrast is taken up by the hepatocytes and excreted via the bile ducts, FNH appeared hyperintense (68%) or isointense (29%). In contrast, all HCAs appeared hypointense in this delayed phase.

Recently, Zech et al. [48] performed a prospective study to evaluate the diagnostic performance of MRI with Primovist in comparison to pre-contrast MRI and dynamic CT in the diagnosis of FNH. They concluded that MRI with Primovist was superior to pre-contrast MRI alone and to dynamic CT. However, mixed uptake in FNH still resulted in misdiagnosis of FNH for HCA in 25 of 59 lesions by 1 of the 3 blinded radiologists.

To sum up, MRI with hepatocyte-specific contrast agents performs better in diagnosing FNH than multi-phase CT scan. The typical enhancement patterns of both FNH and HCA are similar in the arterial and portal venous phase. In contrast to FNH, HCA does not show contrast uptake in the hepatobiliary phase. However, contrast uptake in FNH may show a mixed response making characterization difficult (fig. 6). The central scar in FNH is typically hyperintense on T₂-weighted images and is mainly seen as a hypointense feature on T₁-weighted images in the arterial phase after which it becomes hyperintense in the equilibrium phase. One should also be aware of other hypervascular tumors. Fibrolamellar hepatocellular carcinoma (HCC) may, like FNH, show a central scar that is more coarse and irregular (fig. 7). These scars
do not show late enhancement and the tumor often shows inhomogeneous enhancement and calcifications [29, 59]. Metastasis of renal cell carcinoma may also simulate FNH with a fibrotic central scar (fig. 8). These scars, however, do not show late enhancement. In HCA, an old central bleed may mimic a central scar. Heterogeneity, a peripheral rim and washout phenomena are common for both HCA and well-differentiated HCC (fig. 9). Furthermore, HCA and well-differentiated HCC occasionally show uptake of hepatocyte-specific contrast media, making a definitive diagnosis based on imaging alone impossible [58, 60, 61]. Metastasis from other hypervascular tumors (e.g. neuroendocrine tumors, carcinoid tumors and renal cell carcinoma) will, just as a typical HCA, not show...

Fig. 4. MRI with hepatobiliary contrast agent of a typical FNH. On the blank T1-weighted MRI, the lesion is visible, although isointense with a central scar (a). After contrast the lesion shows strong enhancement with exception of the central scar (b). In the portal venous phase, the lesion is slightly hyperintense with a hypointense central scar (c). In the hepatobiliary phase, the lesion is still hyperintense compared to the normal liver tissue (d).

Fig. 5. MRI with hepatobiliary contrast agent of a ‘typical’ HCA. MRI of multiple typical adenomas in a symptomless female patient. In the arterial phase, there is strong enhancement of the lesion (a). In the portal venous phase, the lesion is isointense (b). Due to rapid washout of contrast (washout phenomenon), the lesion becomes hypointense in the equilibrium phase (c). In the hepatobiliary phase, there is no enhancement of the hepatospecific contrast (d).
Fig. 6. MRI with hepatobiliary contrast agent of atypical FNHs. On $T_1$-weighted arterial phase images, two small lesions with strong homogeneous enhancement are visible (arrows) (a). During the hepatobiliary phase, only a slight ring-like enhancement is shown in the FNH (b).

Fig. 7. MRI with a lesion found in a 15-year-old female with vague abdominal complaints. In the arterial phase, on $T_1$-weighted imaging, strong enhancement of the lesion is seen except for the stellate central area (a). On the $T_2$-weighted image, a low signal of the central ‘scar’ and coarse irregular aspect is clearly visible (b). The final diagnosis was a fibrolamellar HCC.

Fig. 8. MRI of a solitary lesion in a female patient. The lesion existed for 3 years and was considered an FNH. The lesion had increased in size. $T_1$-weighted unenhanced MRI (a). After gadoxetic acid administration, there is strong enhancement of lesion with exception of the central stellate area in the arterial and portal venous phase (b, c). On the $T_2$-weighted image, a high signal of central ‘scar’ is visible (d). In the hepatobiliary phase, there is however no enhancement of contrast (e). The final diagnosis was a solitary metastasis of renal cell carcinoma, 14 years after resection of the primary tumor.
uptake of hepatospecific MR contrast agents. Of note is a recent article in which a correlation is shown between features on MRI and the pathological subclassification of HCAs [62]. A detailed description of this study is however beyond the scope of this article.

**Nuclear Imaging**

On $^{99m}$Tc-sulfur-colloid scintigraphy FNH usually shows normal or increased uptake, while HCA shows no uptake due to lack of functional Kupffer cells [63]. However, contrary to expectations, several studies showed that 30–36% of FNH have decreased uptake [32, 64, 65]. Herman et al. [66] used the $^{99m}$Tc-sulfur-colloid scan preoperatively for the diagnosis of FNH (n = 13) and HCA (n = 10). Atypical findings were that 1 of the 13 FNH showed a decreased uptake and 4 HCAs showed a normal uptake.

The hepatobiliary tracer $^{99m}$Tc-mebrofenin (HIDA) is, like the hepatobiliary MR contrast agents, taken up by functional hepatocytes and excreted into the bile [64]. Since biliary drainage in FNH is reduced compared to normal liver parenchyma, the tracer is retained and visible as a hot spot on delayed images [65]. Evidence on the use of this imaging technique for the differentiation between FNH and HCA is however not available.

In 2007, Bumsel et al. [67] showed promising results in 14 patients in differentiating FNH from HCA using positron emission tomography (PET/CT) in combination with the use of the tracer fluoromethylcholine. So far, no series have however been published using this modality.

**Discussion**

Many imaging modalities are used to visualize FNH and HCA. Based on the typical features, especially FNH can be diagnosed with high certainty on several imaging studies. However, there are atypical findings in both FNH and HCA that preclude a definitive diagnosis and may resemble other tumors. While reviewing the literature, we found many case reports and studies which describe the features of FNH and HCA. However, there is little evidence on the diagnostic performance of imaging modalities in the differentiation of FNH and HCA. In many studies the final diagnosis was often only based on imaging and follow-up, while the gold standard is histopathological confirmation of the tumor. Moreover, the histopathological diagnosis of telangiectatic FNH has recently been reclassified as HCA on the basis of clinical and molecular features [68].

Bartolozzi et al. [13], Dietrich et al. [25] and Ruppert et al. [36] performed a performance study of Doppler-, contrast-enhanced US and multiphase helical CT scan, respectively, in patients with histology proven FNH or HCA. The sample sizes, especially for HCA, were however small. A large prospective, multicenter study conducted by Grazioi et al. [41] assessed the use of Gd-BOPTA MRI for the differentiation of FNH and HCA. They reported a sensitivity of 96.9% and a specificity of 100%. However, a limitation of their study was that the gold standard, i.e. the histological diagnosis, was only available in less than 30% of the FNH lesions. The lack of histological confirmation of all lesions also applies to the

Fig. 9. CT scan of a male bodybuilder using steroids who presented with an acute bleeding. In the arterial phase, a bleeding and multiple enhancing lesions were seen (only one shown) (a). The portal venous and equilibrium phase images showed an inhomogeneous lesion with a washout phenomenon (arrow) (b, c). This washout phenomenon was not found in the other lesions. The presumptive diagnosis was steroid-induced multiple adenomas, but the final diagnosis was HCC with metastases.
retrospective study of Kim et al. [26]. No study compared the use of more than one imaging modality in the differentiation of FNH and HCA.

Because of the lack of reliable evidence, we started a prospective trial to assess the accuracy of several imaging studies for the differentiation of FNH and HCA, termed the DiFA trial which stands for the acronym ‘differentiation of focal nodular hyperplasia and hepatocellular adenoma’. The aim of the DiFA trial is to compare the accuracy of a multiphase CT scan, MRI with Primovist®, PET scan with fluoromethylcholine and contrast-enhanced US for the differentiation of FNH and HCA. The diagnosis based on the different imaging studies is compared with the histological outcome (core biopsy and/or resection specimen). The final aim is to develop a diagnostic algorithm for patients with suspicion of either FNH or HCA in order to obtain a correct diagnosis and provide proper treatment.

References

3. Bioulac-Sage P, Balabaud C, Bedossa P, Noél BN, Flejou JF, Terris B, Belghiti J, Nguyen BN: The DiFA trial which stands for the acronym 'differentiation of focal nodular hyperplasia and hepatocellular adenoma'. The aim of the DiFA trial is to compare the action of focal nodular hyperplasia and hepatocellular adenoma. The final aim is to develop a diagnostic algorithm for patients with suspicion of either FNH or HCA in order to obtain a correct diagnosis and provide proper treatment.

19. Bioulac-Sage P, Balabaud C, Bedossa P, Noél BN, Flejou JF, Terris B, Belghiti J, Nguyen BN: The DiFA trial which stands for the acronym 'differentiation of focal nodular hyperplasia and hepatocellular adenoma'. The aim of the DiFA trial is to compare the action of focal nodular hyperplasia and hepatocellular adenoma. The final aim is to develop a diagnostic algorithm for patients with suspicion of either FNH or HCA in order to obtain a correct diagnosis and provide proper treatment.


